Identifying key predictors of MSI/MMR status in colorectal cancer: Insights from a real-world clinical dataset.

C Cher Bass (Panakeia Technologies, Cambridge, United Kingdom) S Steffen Wolf (Physikalisches Institut, Albert-Ludwigs-Universität Freiburg 1 , D-79104 Freiburg,) F Foivos Ntelemis (Panakeia Technologies, Cambridge, United Kingdom) A Andre Geraldes (Panakeia Technologies Limited, Cambridge, United Kingdom) J Julian Schmidt (Department of Chemistry) N Naren Kumar (Panakeia Technologies, Cambridge, United Kingdom) S Shikha Singhal (Panakeia Technologies Limited, Cambridge, United Kingdom) D Debapriya Mehrotra (Panakeia Technologies, Cambridge, United Kingdom) J James Blackwood (Panakeia Technologies Limited, Cambridge, United Kingdom) C Clare Freer G Grace Rogerson (University of Leeds, Leeds, United Kingdom) M Mitchell Hyde (University of Leeds, Leeds, United Kingdom) B Bejal Mistry N Nicholas Bennett (University of Leeds, Leeds, United Kingdom) E Elizabeth Walsh (University of Leeds, Leeds, United Kingdom) N Nicolas M. Orsi P Pahini Pandya S Salim Arslan (Panakeia Technologies, Cambridge, United Kingdom)

Abstract

e15718 Background: Microsatellite instability (MSI) and mismatch repair (MMR) testing is critical for guiding therapeutic decisions in colorectal cancer (CRC). Despite their clinical importance, routine MSI/MMR testing faces significant challenges, including high costs, long turnaround times, and pathology workforce shortages. Artificial intelligence (AI) offers opportunities to overcome these barriers through data-driven solutions. To maximize the clinical utility and performance of AI-based approaches, it is crucial to identify and analyze the key predictors of MSI/MMR status. Such analysis not only aids in developing more accurate predictive models, but also supports efforts to adapt diagnostic tools to diverse patient populations. To this end, we conducted a comprehensive study with a real-world clinical dataset of retrospective CRC cases to identify the critical factors associated with MSI/MMR status. Methods: Clinical and histopathological data from 800 CRC cases at St James’s University Hospital (UK) were analyzed using a random forest (RF) classifier to identify the most important predictors for determining the overall MSI/MMR status. MSI/MMR testing was done as part of routine clinical care, with 11.9% of cases classified as MMR-deficient/MSI-high (n = 95). Normalized importance values were computed for each feature to quantify their contribution. Pairwise correlation analysis was conducted using Cramer's V and Chi-squared tests to evaluate interdependencies among features. The cohort included 308 patients (38.5%) under 65 years of age and 492 patients (61.5%) aged 65 or older, with a higher proportion of males (n = 453, 56.6%) compared to females (n = 347, 43.4%). The majority of patients were diagnosed with Stage II and III cancers (n = 557, 69.6%) and had tumors graded as moderately differentiated (n = 620, 78.6%). The primary tumor site was the colon (n = 528, 66.0%) and the most common histological subtype was adenocarcinoma (n = 686, 85.8%). Results: The classifier identified age as the most influential feature associated with MSI/MMR status, with an importance of 52.9%. Stage and grade were the next most significant contributors, accounting for 17.0% and 12.2%, respectively. Histological subtype and tumor site were less influential, with contributions of 7.8% and 6.0%, respectively. Gender was the least impactful factor, with an importance of 4.1%. Pairwise correlation analysis showed weak associations among individual features, with all Cramer's V values below 0.26 and Chi-squared tests indicating statistical significance (p < 0.001). Conclusions: Our analysis highlights the role of age, stage, and grade in determining MSI/MMR status, with minimal interdependencies among features. These results provide valuable insights for refining predictive models and advancing the development of reliable, generalizable diagnostic tools for diverse CRC patient populations.

Article Details

Volume / Issue Vol. 43, Issue 16_suppl
Published June 01, 2025
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (18)

C

Cher Bass

Panakeia Technologies, Cambridge, United Kingdom

S

Steffen Wolf

Physikalisches Institut, Albert-Ludwigs-Universität Freiburg 1 , D-79104 Freiburg,

F

Foivos Ntelemis

Panakeia Technologies, Cambridge, United Kingdom

A

Andre Geraldes

Panakeia Technologies Limited, Cambridge, United Kingdom

J

Julian Schmidt

Department of Chemistry

N

Naren Kumar

Panakeia Technologies, Cambridge, United Kingdom

S

Shikha Singhal

Panakeia Technologies Limited, Cambridge, United Kingdom

D

Debapriya Mehrotra

Panakeia Technologies, Cambridge, United Kingdom

J

James Blackwood

Panakeia Technologies Limited, Cambridge, United Kingdom

C

Clare Freer

G

Grace Rogerson

University of Leeds, Leeds, United Kingdom

M

Mitchell Hyde

University of Leeds, Leeds, United Kingdom

B

Bejal Mistry

N

Nicholas Bennett

University of Leeds, Leeds, United Kingdom

E

Elizabeth Walsh

University of Leeds, Leeds, United Kingdom

N

Nicolas M. Orsi

P

Pahini Pandya

S

Salim Arslan

Panakeia Technologies, Cambridge, United Kingdom